Clinical trials: Frequency Lowering
Urinary Bladder, Overactive
A Study of YM178 in Subjects With Symptoms of Overactive Bladder
This study is to assess the efficacy and safety of YM178 in patients with symptoms of overactive bladder.
- Trial name
- NCT01043666
- Testing
- YM178, tolterodine ER
- Where
- 35 sites in China, India and 2 more
- Volunteers
- 1,126 people
- Sponsor
- Astellas Pharma Inc
Urinary Bladder, Overactive
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
- Trial name
- SCORPIO (NCT00689104)
- Testing
- Mirabegron, Tolterodine
- Where
- 218 sites in Australia, Austria and 28 more
- Volunteers
- 2,336 people
- Sponsor
- Astellas Pharma Inc
Multiple Myeloma
Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma
The purpose of this study is to determine whether lower than conventional doses of dexamethasone and thalidomide; and a higher dosing frequency of zoledronic acid are effective in the treatment of newly-diagnosed multiple myeloma.
- Trial name
- dtZ (NCT00263484)
- Testing
- dexamethasone, thalidomide, zoledronic acid
- Where
- 10 sites in India, Singapore and 1 more
- Volunteers
- 56 people
- Sponsor
- Gleneagles Hospital
Overactive Bladder Syndrome, Urinary Urge Incontinence
Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial
Overactive bladder is a common condition that causes sudden urges to urinate, frequent urination, night-time urination, and sometimes leakage of urine.
- Conditions
- Overactive Bladder Syndrome, Urinary Urge Incontinence, Detrusor Overactivity
- Trial name
- NCT07184307
- Testing
- Platelet-Rich Plasma, Intravesical Botulinum Toxin Injection
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Benha University
Lower Urinary Tract Symptoms
Comparison of 2 Extracts of Saw Palmetto Versus Placebo on Lower Urinary Tract Symptoms (LUTS) and Urinary Frequency
A randomized, double-blind, placebo-controlled, parallel group study to compare 2 extracts of saw palmetto versus placebo on lower urinary tract symptoms and urinary frequency in 120 generally healthy participants, 45 - 80 years.
- Trial name
- NCT06266000
- Testing
- Saw palmetto extract 320mg per day, Commercial Saw palmetto extract 320mg per day, Palm Oil capsule
- Where
- Australia
- Volunteers
- 89 people
- Sponsor
- RDC Clinical Pty Ltd
Overactive Bladder
Therapy of the Overactive Bladder Syndrome
The aim of the present study is to investigate in patients with overactive bladder syndrome (OABS) whether a combination treatment of solifenacin with pelvic floor muscle training and whole body vibration training achieves a…
- Trial name
- TOBS (NCT01314781)
- Testing
- solifenacin, PFMT and WBVT
- Where
- Switzerland
- Volunteers
- 66 people
- Sponsor
- Cantonal Hospital, Frauenfeld
Urinary Incontinence
Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women
The purpose of the study is to assess the impact of treatment with tolterodine ER versus placebo on Urgency Urinary Incontinence in sexually active women with OAB symptoms.
- Trial name
- NCT00143481
- Testing
- Tolterodine ER 4mg QD
- Where
- 58 sites in United States
- Volunteers
- 400 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder
Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder
To compare the effect of tolterodine ER 4 mg to placebo on patient reported outcomes in subjects with overactive bladder after 1, 4, and 12 weeks of treatment using an innovative web-based trial design
- Trial name
- REMOTE (NCT01302938)
- Testing
- Tolterodine ER
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder, Urinary Incontinence, Urge
Efficacy of Li-SWT on Persistent Storage Symptoms After Transurethral Surgery for BPO
comparing the outcome of low-intensity shock wave therapy (Li-SWT) versus solifenacin on persistent storage symptoms after transurethral surgery for benign prostatic obstruction (BPO)
- Conditions
- Overactive Bladder, Urinary Incontinence, Urge, Urgency-frequency Syndrome, Post Prostatectomy
- Trial name
- NCT04437108
- Testing
- Li-SWT (suprapubic approach), Li-SWT (perineal approach), Li-SWT (combined approach)
- Where
- Egypt
- Volunteers
- 132 people
- Sponsor
- Mansoura University
Overactive Bladder, Overactive Detrusor
Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections
There is some evidence to suggest standard urine cultures may not be adequate in identifying patients with low grade urinary tract infections.
- Conditions
- Overactive Bladder, Overactive Detrusor, Urgency-Frequency Syndrome, UTI
- Trial name
- NCT03080389
- Testing
- Extended Urine Culture
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The Cleveland Clinic
Urinary Bladder, Overactive
A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder
The purpose of this study is to explore additional benefit of solifenacin after 12-week treatment, compared with alpha blocker monotherapy in men with residual OAB symptoms.
- Trial name
- NCT00699049
- Testing
- Alpha blocker, solifenacin
- Where
- 3 sites in South Korea
- Volunteers
- 94 people
- Sponsor
- KYU-SUNG LEE
Overactive Bladder (OAB), Refractory Overactive Bladder
Cefar URO - Symptomatic Treatment of Overactive Bladder
A Post-Market Prospective Clinical Investigation to collect PMCF data on the safety and performance of the Cefar URO device when using the preset program P4 (parameter setting: frequency 20Hz, pulse width 200μs) for the…
- Conditions
- Overactive Bladder (OAB), Refractory Overactive Bladder, Urinary Urgency and Frequency
- Trial name
- NCT06659536
- Testing
- Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro Device
- Where
- France
- Volunteers
- 53 people
- Sponsor
- DJO UK Ltd
Overactive Bladder, Urge Urinary Incontinence
Pelvic Floor Muscle Training With Leva System for Urge Incontinence
This is a pilot non-comparative study to assess the effectiveness of pelvic floor muscle training guided by the leva® system for improving change in subject-reported incontinence-related quality of life and urgency urinary…
- Conditions
- Overactive Bladder, Urge Urinary Incontinence, Mixed Urinary Incontinence
- Trial name
- NCT03923348
- Testing
- Leva device
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The Christ Hospital
Overactive Bladder
Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home
This pilot clinical study, which focuses on feasibility and proof-of-principle, will be conducted in 11 female subjects (55-100 years old) with UI.
- Trial name
- OAB Aim 2 (NCT03595215)
- Testing
- TENS
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Theranova, L.L.C.
Overactive Bladder, Urinary Urgency Incontinence
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
- Conditions
- Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer
- Trial name
- NCT06511141
- Testing
- Axonics SNM System
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- Axonics, Inc.
Urinary Incontinence, Fecal Incontinence
Safety and Performance of UCon for the Treatment of the Symptoms of Overactive Bladder (OAB) / Bowel Dysfunction (BD)
This clinical investigation is a single-arm, prospective, multicentre, early feasibility study, which is used to evaluate the device design of UCon with respect to initial clinical safety and device performance in a small number…
- Conditions
- Urinary Incontinence, Fecal Incontinence, Urge Incontinence, Nocturia
- Trial name
- NCT05368246
- Testing
- UCon
- Where
- 3 sites in Denmark
- Volunteers
- 80 people
- Sponsor
- InnoCon Medical
Overactive Bladder
Utilization of the BIOWAVE Device to Treat Overactive Bladder
Demonstrate a response to stimulation of the posterior tibial nerve using the Biowave device and a microneedle patch electrode in patients with overactive bladder symptoms.
- Trial name
- OAB (NCT01848366)
- Testing
- Biowave Treatment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Kenneth Peters, MD
Overactive Bladder
Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)
The purpose of this study is to determine whether the non-invasive neurostimulation patch is effective in the treatment of urgency, frequency and urge (urinary) incontinence.
- Trial name
- NCT01125722
- Testing
- Non-invasive neurostimulation device
- Where
- 11 sites in United States, Sweden and 1 more
- Volunteers
- 74 people
- Sponsor
- Ethicon Endo-Surgery
Back Pain Lower Back Chronic, Chronic Pain
Examining the Impact of a Digital Health Program and TENS Device for Patients With Chronic Low Back Pain
The goal of this study is to examine the extent to which Hinge Health, a digital musculoskeletal program, and Enso, a wearable pain relief device, have clinically significant impact on the pain, function, and health care use…
- Conditions
- Back Pain Lower Back Chronic, Chronic Pain, Musculoskeletal Pain
- Trial name
- NCT07011537
- Testing
- Digital Musculoskeletal (MSK) Program, Transcutaneous Electrical Nerve Stimulation (TENS), Standard of Care (SOC)
- Where
- United States
- Volunteers
- 196 people
- Sponsor
- Hinge Health, Inc
Overactive Bladder
A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder
To evaluate the efficacy and the safety of KUC-7483 in overactive bladder patients.
- Trial name
- NCT01004315
- Testing
- KUC-7483, Tolterodine
- Where
- Japan
- Volunteers
- 750 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.